Evoke Pharma Inc ( EVOK )

Other

Common Stock

2,330

-^{footnote F1}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,479

-^{footnote F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

8,750

-^{footnote F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,291

-^{footnote F2}

Footnote F1 (price): On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and… Full note on SEC EDGAR
Footnote F2 (price): After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger… Full note on SEC EDGAR

Dec 16, 2025

Other

Common Stock

133

-^{footnote F1}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,218

-^{footnote F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,218

-^{footnote F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

5,833

-^{footnote F2}

Footnote F1 (price): On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and… Full note on SEC EDGAR
Footnote F2 (price): After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger… Full note on SEC EDGAR

Dec 16, 2025

Mark Kowieski - Officer

Other

Common Stock

11,815

-^{footnote F1}

Dec 17, 2025

Mark Kowieski - Officer

Derivative

Stock Option (Right to Buy)

17,291

-^{footnote F2}

Dec 17, 2025

Mark Kowieski - Officer

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F2}

Footnote F1 (price): On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and… Full note on SEC EDGAR
Footnote F2 (price): After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger… Full note on SEC EDGAR

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,187

-^{footnote F1,F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,187

-^{footnote F1,F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

5,833

-^{footnote F1,F2}

Footnote F1 (price): In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled… Full note on SEC EDGAR

Dec 16, 2025

Other

Common Stock

-^{footnote F1}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,218

-^{footnote F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

5,833

-^{footnote F2}

Dec 17, 2025

Derivative

Stock Option (Right to Buy)

1,187

-^{footnote F2}

Footnote F1 (price): On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and… Full note on SEC EDGAR
Footnote F2 (price): After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger… Full note on SEC EDGAR

Dec 17, 2025

Vickie S. Reed

Derivative

Stock Option (Right to Buy)

1,250

-^{footnote F1,F2}

Dec 17, 2025

Vickie S. Reed

Derivative

Stock Option (Right to Buy)

1,250

-^{footnote F1,F2}

Dec 17, 2025

Vickie S. Reed

Derivative

Stock Option (Right to Buy)

5,833

-^{footnote F1,F2}

Footnote F1 (price): In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled… Full note on SEC EDGAR

Dec 16, 2025

Matthew J. D'Onofrio - Officer

Other

Common Stock

15,509

-^{footnote F1}

Dec 17, 2025

Matthew J. D'Onofrio - Officer

Derivative

Stock Option (Right to Buy)

64,840

-^{footnote F2}

Dec 17, 2025

Matthew J. D'Onofrio - Officer

Derivative

Stock Option (Right to Buy)

70,000

-^{footnote F2}

Footnote F1 (price): On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and… Full note on SEC EDGAR
Footnote F2 (price): After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger… Full note on SEC EDGAR

Nov 6, 2025

Roger M. Klein - 10% Owner

Open-market sale

Common Stock

5,000

$10.66^{footnote F1}

$53K

Nov 6, 2025

Roger M. Klein - 10% Owner

Open-market sale

Common Stock

4,000

$10.65

$43K

Footnote F1 (price): Price reflects the weighted average sale price for the shares, which were sold in multiple transactions at prices that ranged from $10.65 to $10.66. Upon request, the Reporting Person will provide information regarding the number of shares sold at each price within the range to… Full note on SEC EDGAR

May 21, 2025

Grant or award

Stock Option (Right to Buy)

1,187

$0.00

May 21, 2025